LOPID® (gemfibrozil tablets, USP) is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.
LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for:
- Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. LOPID therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of LOPID therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5).
- Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS, PRECAUTIONS, and CLINICAL PHARMACOLOGY). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. LOPID IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY.
In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I).
The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.
Media Articles Related to Lopid (Gemfibrozil)
FDA Approves Cangrelor (Kengreal) for PCI
Source: theheart.org | Medscape Cardiology Headlines [2015.06.22]
The approval in the PCI setting is based on data from CHAMPION-PHOENIX, where cangrelor reduced the risk of thrombotic events compared with patients treated clopidogrel.
Published Studies Related to Lopid (Gemfibrozil)
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. [2011.05]
INTRODUCTION: Metabolic syndrome is a powerful predictor of cardiovascular events independent of overt diabetes. Dietary restriction and weight loss modify metabolic syndrome components. This study addresses whether combination pharmacologic therapy focused on dyslipidemia provides additional benefit... CONCLUSIONS: The combination of gemfibrozil, niacin and cholestyramine has profound, beneficial effects on the components of metabolic syndrome. These benefits are additive to those seen with aggressive diet and lifestyle modification.
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. [2011.04]
To study the time to onset of mechanism-based inactivation of cytochrome P450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers.The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clinical practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. [2011.03]
Coadministration of statins and fibrates is beneficial in some patients by allowing simultaneous reduction of triglycerides and low-density lipoprotein cholesterol alongside elevation of high-density lipoprotein cholesterol. However, the potential for drug interactions must be taken into consideration.
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. [2011.02]
PURPOSE: Gemfibrozil, a strong inhibitor of cytochrome P450 (CYP) 2C8 in vivo, was recently found to markedly increase the plasma concentrations of montelukast in humans. Like montelukast, zafirlukast is a substrate of CYP2C9 and CYP3A4 and a potent inhibitor of CYP2C8 in vitro. To investigate the contribution of CYP2C8 to the metabolism of zafirlukast in vivo, we studied the effect of gemfibrozil on the pharmacokinetics of zafirlukast... CONCLUSIONS: Gemfibrozil has no effect on the pharmacokinetics of zafirlukast, indicating that CYP2C8 does not play a significant role in the elimination of zafirlukast.
The effect of gemfibrozil, niacin and cholestyramine combination therapy on
metabolic syndrome in the Armed Forces Regression Study. 
pharmacologic therapy focused on dyslipidemia provides additional benefit... CONCLUSIONS: The combination of gemfibrozil, niacin and cholestyramine has
Clinical Trials Related to Lopid (Gemfibrozil)
Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil [Completed]
Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil [Active, not recruiting]
This study will determine whether the protease inhibitor lopinavir/ ritonavir (Kaletra™
(Trademark)), which is used to treat HIV disease, lowers blood levels of the lipid-regulating
drug gemfibrozil (Lopid™ (Trademark)) in HIV-negative healthy volunteers. Many patients with
HIV infection who take protease inhibitors have abnormally high lipids (cholesterol and
triglycerides). Gemfibrozil, commonly used to treat high triglycerides, often is not
effective in HIV-infected patients taking protease inhibitors, possibly because of an
interaction between the two medicines that causes a lowering of gemfibrozil's levels in the
blood. Results from this study will give researchers information on whether lopinavir/
ritonavir affects the blood levels of gemfibrozil.
Healthy, normal volunteers between 18 and 65 years old who test negative for HIV may be
eligible for this study.
On study day 1, subjects have a blood sample drawn from a catheter inserted into a vein in
the arm to determine pre-dosing blood levels of gemfibrozil. They then take a gemfibrozil
tablet and are given breakfast 30 minutes after taking the drug. Blood samples are obtained
through the catheter at 0, 1, 1. 5, 2, 3, 4, 6, 8, 12, and 24 hours after dosing to determine
gemfibrozil levels at those intervals. At the end of 12 hours, the catheter is removed and
the subject is discharged from the clinic. The next morning subjects return to the clinic for
another blood sample, collected through a vein in the arm.
Subjects begin taking lopinavir/ ritonavir between 7 and 35 days after their first dose,
depending on their schedule and the clinic schedule. On the fourteenth day of dosing subjects
come to the clinic and are given a single dose of gemfibrozil, as on study day 1, and have
breakfast 30 minutes later. Blood samples are collected to determine gemfibrozil levels just
like on study days 1 and 2. An additional sample is collected for routine lab tests.
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors [Recruiting]
GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor
that is being developed for the treatment of BRAF mutation-positive tumors. This is a
4-part study (in 4 separate cohorts of subjects) designed to examine the interaction
potential of GSK2118436, either as a perpetrator (i. e., effect of GSK2118436 on warfarin;
Part A) or victim (i. e., effect of other drugs on GSK2118436; Part B: ketoconazole and Part
C: gemfibrozil), as well as to evaluate the single and repeat dose pharmacokinetic
parameters of GSK2118436 (Part D). A sufficient number of subjects will be screened to
obtain approximately 12 evaluable subjects each for Part A, Part B, Part C and Part D.
Following completion of this study, subjects may continue dosing with GSK2118436 in the
roll-over study, Protocol BRF114144.
Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered [Recruiting]
Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction [Recruiting]
The purpose of this study is to investigate the effect of gemfibrozil on nicotine
reinforcement and cue-elicited craving. Other objectives of this study include screening for
the ability of gemfibrozil to aid smoking abstinence during a brief quit attempt and
examining the validity of using laboratory measures of tobacco dependence to predict smoking
abstinence. It is hypothesized that gemfibrozil will result in diminished nicotine
reinforcement, an attenuated response to smoking cues, and an increase in smoking abstinence
compared with placebo. It is also hypothesized that the laboratory measures will prove valid
in predicting abstinence.
Reports of Suspected Lopid (Gemfibrozil) Side Effects
Weight Decreased (10),
Blood Triglycerides Increased (10),
Drug Hypersensitivity (9),
Abdominal Discomfort (8),
Intracranial Aneurysm (7),
Malaise (6), more >>
Page last updated: 2015-06-22